Adherence to dosing schedule of denosumab therapy for osteoporosis during COVID-19 lockdown: an electronic medical record and pharmacy claims database study from Asia

Osteoporosis care during the COVID-19 pandemic in the Netherlands: A national survey

(2021) Joséphine Jeanne Maria Peeters et al.   Archives of Osteoporosis

Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region

(2021) M. Chandran et al.   OSTEOPOROSIS INTERNATIONAL

How has COVID-19 affected the treatment of osteoporosis? An IOF-NOF-ESCEO global survey

(2021) N. R. Fuggle et al.   OSTEOPOROSIS INTERNATIONAL

Poor adherence to parenteral osteoporosis therapies during COVID-19 pandemic

(2021) Roland Kocijan et al.   Archives of Osteoporosis

Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based Study

(2020) Houchen Lyu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis

(2020) Houchen Lyu et al.   ANNALS OF INTERNAL MEDICINE

IMPACT-Scot report on COVID-19 and hip fractures

(2020) Andrew J. Hall et al.   Bone & Joint Journal

Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS

(2020) Elena Tsourdi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Undertreatment of osteoporosis following hip fracture: a retrospective, observational study in Singapore

(2020) Yi Ting Chau et al.   Archives of Osteoporosis

Advanced motor driving circuit with improved transfer efficiency based on adaptive segmented control

(2020) Kui Ma et al.   IEICE Electronics Express

The health and economic burden of osteoporotic fractures in Singapore and the potential impact of increasing treatment rates through more pharmacological options

(2019) Manju Chandran et al.   Archives of Osteoporosis

Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study

(2018) Stuart L. Silverman et al.   Archives of Osteoporosis

Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium

(2017) A. Fahrleitner-Pammer et al.   Archives of Osteoporosis

Persistence with denosumab and zoledronic acid among older women: a population-based cohort study

(2016) Éric Tremblay et al.   Archives of Osteoporosis

Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program

(2015) Alexandra Papaioannou et al.   CURRENT MEDICAL RESEARCH AND OPINION

SAT0479 Early Findings from Prolia® Post-Marketing Safety Surveillance for Atypical Femoral Fracture, Osteonecrosis of the Jaw, Severe Symptomatic Hypocalcemia, and Anaphylaxis

(2014) M. Geller et al.   ANNALS OF THE RHEUMATIC DISEASES

Persistence with osteoporosis medication among newly-treated osteoporotic patients

(2013) Job F. M. van Boven et al.   JOURNAL OF BONE AND MINERAL METABOLISM

A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System

(2011) J. Devine et al.   OSTEOPOROSIS INTERNATIONAL

Adherence to osteoporosis medications amongst Singaporean patients

(2011) M. H. H. Cheen et al.   OSTEOPOROSIS INTERNATIONAL

Adherence to treatment of primary osteoporosis and its association to fractures—the Swedish Adherence Register Analysis (SARA)

(2011) E. Landfeldt et al.   OSTEOPOROSIS INTERNATIONAL

Measuring and improving adherence to osteoporosis pharmacotherapy

(2010) Suzanne M Cadarette et al.   CURRENT OPINION IN RHEUMATOLOGY

Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe

(2009) Ethel S. Siris et al.   AMERICAN JOURNAL OF MEDICINE

Comparison of Drug Adherence Rates Among Patients with Seven Different Medical Conditions

(2008) Becky A Briesacher et al.   PHARMACOTHERAPY